Back to Ovarian Endometrioid Adenocarcinoma

Ovarian Endometrioid Adenocarcinoma — Clinical Trials

MONDO:000633525 active·9 recruitingLast updated: Mar 20, 2026, 10:49 PM

Trial Landscape

Ovarian Endometrioid Adenocarcinoma has an active clinical trial landscape, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment23

Procedure17

Biological Therapy12

13 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

1 trials are observational or have no phase designation.

Sponsor Types

NIH15Academic/Other8Collaborative Network2Industry1

Top Sponsors

Nuvectis Pharma, Inc.

Trial Locations

United States24 trials

Canada6 trials

South Korea4 trials

Japan3 trials

Puerto Rico3 trials

Switzerland2 trials

Italy1 trial

Mexico1 trial

Netherlands1 trial

Singapore1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

26 Trials

Phase 3Recruiting

NCT04575935

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2020Est. completion: Dec 2028Updated: Mar 2026

Phase 3Recruiting

NCT04111978

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Sponsor:Swiss GO Trial Group

AustriaStarted: Nov 2020Est. completion: Jul 2032Updated: Sep 2025

Phase 2Recruiting

NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Mar 2024Est. completion: Dec 2026Updated: Mar 2026

Phase 2Recruiting

NCT06639074

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Sponsor:Mayo Clinic

United StatesStarted: Nov 2024Est. completion: Dec 2027Updated: Oct 2025

Phase 2Recruiting

NCT04919629

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Sponsor:Roswell Park Cancer Institute

United StatesStarted: Apr 2023Est. completion: Apr 2027Updated: May 2025

Phase 1Recruiting

NCT05950464

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2023Est. completion: Apr 2026Updated: Mar 2026

Phase 1Recruiting

NCT05920798

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Sponsor:Mayo Clinic

United StatesStarted: Sep 2023Est. completion: Jul 2027Updated: Jun 2025

Early Phase 1Recruiting

NCT05415709

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:Ohio State University Comprehensive Cancer Center

United StatesStarted: Jun 2022Est. completion: Dec 2026Updated: Feb 2026

Not ApplicableRecruiting

NCT06466382

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Sponsor:Swiss GO Trial Group

SwitzerlandStarted: Mar 2025Est. completion: Sep 2028Updated: Jan 2026

Phase 3Active, Not Recruiting

NCT01167712

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Sep 2010Est. completion: Jul 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT02446600

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Mar 2016Est. completion: Nov 2026Updated: Mar 2026

Phase 3Active, Not Recruiting

NCT00565851

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2007Est. completion: Jan 2028Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT04034927

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03348631

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02839707

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2017Est. completion: Mar 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02101775

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2014Est. completion: Mar 2027Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04739800

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2021Est. completion: Nov 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02502266

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2016Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03587311

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2018Est. completion: Oct 2026Updated: Oct 2025

Stay informed about clinical trials for Ovarian Endometrioid Adenocarcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 10:49 PM

Ovarian Endometrioid Adenocarcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

26 Trials

Open Trials9

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Active Trials16

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Other1